Regulatory Compliance and Quality
Regulatory Compliance and Quality
MDR compliance built on clinical evidence and risk control
Managing MDR Compliance
Regulation (EU) 2017/745 (EU MDR) defines how medical devices are assessed and maintained on the EU market.
Clinical data play a central role across the entire product lifecycle, including clinical evaluation, post-market activities and conformity assessment. Expectations focus on data consistency, traceability and alignment with regulatory requirements.
KCRI supports manufacturers in structuring and managing clinical development programmes that address these requirements across both pre-market and post-market phases.
How we approach MDR compliance
MDR compliance requires coordination between clinical evidence, regulatory strategy and quality systems.
KCRI supports this integration across the full product lifecycle, from early development to post-market activities.
Lifecycle perspective
MDR compliance extends beyond initial certification.
It requires continuous alignment of clinical data, regulatory strategy and quality systems throughout the product lifecycle.
Where MDR risk actually emerges
Regulatory risk rarely originates at the documentation stage.
It emerges earlier — in clinical evidence, data consistency and assumptions built into the development process.
KCRI addresses these areas to ensure that regulatory requirements are supported by consistent and interpretable clinical data.
Where MDR compliance becomes challenging
MDR challenges arise in how clinical data are generated, structured and maintained over time across clinical evaluation, PMS and PMCF.
Inconsistencies across these areas may lead to delays, rework and increased scrutiny during regulatory review.
Typical challenges include:
– inconsistent clinical data across studies and lifecycle stages
– misalignment between clinical evaluation and post-market data
– disconnect between study design and regulatory strategy
– fragmentation between clinical, regulatory and quality functions
KCRI addresses these challenges by aligning clinical development, regulatory requirements and quality systems into a consistent and structured approach.
What this means for manufacturers
– consistent clinical evidence across the product lifecycle
– alignment with regulatory expectations and notified body requirements
– improved readiness for audits and regulatory review
– reduced risk of delays in certification and post-market compliance
FDA and US market perspective
Beyond EU MDR, KCRI supports projects intended for the US market, where clinical evidence needs to address FDA expectations, study design requirements and regulatory decision-making pathways.
We help manufacturers and sponsors structure clinical development programmes with consideration for both European and US regulatory environments, supporting data consistency, interpretability and readiness for regulatory review.
ATMP and innovative therapies
KCRI is also involved in projects related to advanced and innovative therapeutic approaches, including Advanced Therapy Medicinal Products (ATMPs).
These projects require early coordination between clinical development, regulatory strategy, quality requirements and evidence generation. KCRI supports this process by helping sponsors structure clinical research activities in a way that reflects the scientific complexity, regulatory expectations and long-term development needs of advanced therapies.
Quality system
KCRI operates under certified quality and information security management systems, supporting consistent and secure clinical research operations.
Certification body:
TÜV Rheinland®
Scope of certification:
– selection of clinical trial sites
– clinical and regulatory support, including GCP
– planning, management and supervision of clinical trials, Phase I–IV, including First-in-Human studies
– independent, standardized analysis of angiographic images, intravascular ultrasound and ECG.
